1. Home
  2. TY vs NVAX Comparison

TY vs NVAX Comparison

Compare TY & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tri Continental Corporation

TY

Tri Continental Corporation

HOLD

Current Price

$34.83

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.93

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TY
NVAX
Founded
1929
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.5B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
TY
NVAX
Price
$34.83
$8.93
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$11.33
AVG Volume (30 Days)
34.4K
4.4M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
3.36%
N/A
EPS Growth
N/A
309.76
EPS
4.78
N/A
Revenue
N/A
$1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.29
N/A
Revenue Growth
N/A
64.69
52 Week Low
$30.53
$6.20
52 Week High
$36.03
$11.85

Technical Indicators

Market Signals
Indicator
TY
NVAX
Relative Strength Index (RSI) 48.98 46.20
Support Level $34.20 $8.89
Resistance Level $34.79 $9.02
Average True Range (ATR) 0.64 0.60
MACD -0.07 -0.08
Stochastic Oscillator 28.68 36.52

Price Performance

Historical Comparison
TY
NVAX

About TY Tri Continental Corporation

Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: